Immunotherapy plus targeted therapy for liver cancer with lung spread
Part of Cancer clinical trials.
This trial tests giving a combination of two drugs — an immunotherapy (camrelizumab) and a targeted therapy (rivoceranib) — along with local treatments like ablation or radiation, for liver cancer that has spread to the lungs. The goal is to see if this approach is safe and effective, and it may help shrink lung tumors and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that has spread to your lungs, with no more than 5 spots in the lungs.
- You have not had any prior systemic treatment (like chemotherapy or targeted pills) for your liver cancer.
- Your liver function is good (Child-Pugh A or B, score 7 or less).
- You are well enough to undergo a local treatment like ablation or radiation for the lung tumors.
- Your blood counts, kidney function, and clotting are within normal limits.
- You are between 18 and 85 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests a combination of radiation therapy, an immunotherapy drug called camrelizumab, and a targeted therapy pill called apatinib for people with advanced liver cancer that has spread to the main blood vessel of the liver. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
Hear when a new Hepatecellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.